First Reported U.S. H5N1 Death, COVID Shot Brain Damage & Hundreds of Operational Biolabs

January 7, 2025

https://petermcculloughmd.substack.com/p/first-reported-us-h5n1-bird-flu-death?

First Reported U.S. H5N1 Bird Flu Death, COVID-19 ‘Vaccine’ Brain Damage, and Hundreds of Operational Biolabs

Epidemiologist Nicolas Hulscher on Brannon Howse Live
 
Nicolas Hulscher, MPH
Jan 07, 2025

Please enjoy my interview on Worldview Tube with Brannon Howse, where we discuss breaking public health developments:

  1. The first H5N1 bird flu death ever reported in the United States: The Louisiana Department of Health should release more details — This patient was over 65 years old with multiple underlying health conditions. It’s entirely possible that these pre-existing conditions were the primary cause of death, rather than H5N1 itself. A few weeks ago, Labcorp launched an H5N1 bird flu PCR test in the U.S., now available for order through physicians. As a result, we can expect the Biopharmaceutical Complex to soon use falsely inflated PCR ‘case counts’ and the first reported death as tools to increase public fear of bird flu, driving higher demand for bird flu vaccinations.

  2. Catastrophic Neurological and Psychiatric Damage from COVID-19 ‘Vaccines’: Increased risks of ischemic stroke, hemorrhagic stroke, transient ischemic attack, myelitis, myasthenia gravis, Alzheimer’s disease, cognitive impairment, depression, anxiety, and sleep disorders.

  3. Biolabs: We need a clean sweep of the hundreds of operational BSL3/BSL4 biolabs that possess modified pathogens with pandemic potential, most of which are located in dense population centers. Since 2001, there have been ~300 confirmed biolab pathogen leaks globally, with the vast majority (78.6%) occurring in the United States. State-sponsored bio-terrorism must be SHUT DOWN to prevent another man-made pandemic.

_______________

For More:

Category:

Activism, vaccines, Viruses

Comments Off on First Reported U.S. H5N1 Death, COVID Shot Brain Damage & Hundreds of Operational Biolabs

Despite Mounting Evidence & Data, COVID Shots Continue to Kill & Maim

Despite all common sense, repeated warnings, and:

they still have not been removed! 

And now world leaders in 10 countries have received ‘notice of extreme concern’ from a team of experts who are calling for the shots to be banned from public use.

https://lionessofjudah.substack.com/p/global-covid-vaccine-damage-estimates?

Global COVID ‘Vaccine’ Damage Estimates by Edward Dowd

“Killed: 7.5 – 15 million people, Disabled: 29 – 60 million people, Injured: 500 – 900 million people….Arrests made: ZERO”

Lioness of Judah Ministry
Dec 29, 2024
Global COVID ‘vaccine’ damage estimates by ex-BlackRock executive, whistleblower, Ed Dowd:

Killed: 7.5 – 15 million people

Disabled: 29 – 60 million people

Injured: 500 – 900 million people

5 billion people received mRNA shot(s)

Arrests made: ZERO

Notice that the world appears to be in a constant wars, but in a matter of months every country magically agreed to use an untested, experimental ‘vaccine’ with lipid nanoparticles.

Source: EDWARD DOWD

https://petermcculloughmd.substack.com/p/vast-mrna-vaccine-biodistribution?

Vast mRNA ‘Vaccine’ Biodistribution, Persistence, and Adjuvant Toxicity Research Library Published

Over 100 peer-reviewed studies demonstrate serious safety concerns.

Nicolas Hulscher, MPH
Dec 28, 2024

A comprehensive research library that contains over 100 peer-reviewed studies (n=130) documenting mRNA “vaccine” biodistribution, persistence, and adjuvant toxicity has just been published (Compiled by Dr. Martin Wucher, MSC Dent Sc (eq DDS), Dr. Byram Bridle, PhD, Erik Sass, et al). You can read it here.

Be sure to also check out their massive Spike protein Pathogenicity Research Library, which has now been updated to include 320 peer reviewed studies.

For those who still believe COVID-19 injections are safe, I encourage you to carefully review the over 400 peer-reviewed studies available in both libraries and then reassess your position.

Nicolas Hulscher, MPH

Epidemiologist and Foundation Administrator, McCullough Foundation

http://www.mcculloughfnd.org

_______________


Recently Steve Kirsch gave the following information:
There is no Autism in the Amish community as well as any of the other newer diseases such as ADD, autoimmune disease, PANDAS, PANS, epilepsy, etc.  The U.S. has been studying the Amish for decades, but there’s never been a public report.  The reason is it would show that if you don’t follow government guidelines you’re going to end up healthier.

Category:

Activism, vaccines, Viruses

Comments Off on Despite Mounting Evidence & Data, COVID Shots Continue to Kill & Maim

Lyme Disease Research in Review: Triumphs, Trials, and the Path Forward

https://www.lymedisease.org/lyme-disease-research-review/

Lyme disease research in review: triumphs, trials, and the path forward

As always, the world of Lyme is complicated with both good news and bad. Looking back over the past year, I want to highlight a few of the biggest scientific advances that stand out in my mind.

Co-Infections

First I want to share something that science keeps validating—the majority of patients with persistent symptoms following a diagnosis of Lyme disease have co-infections.

This means they are infected with two or more pathogens (such as bacteria, viruses, or fungi) at the same time. These co-infections (including COVID-19) complicate the immune response and likely increase the chance of developing chronic Lyme.

As I wrote about previously, North America is “ground zero” for babesiosis, which is likely playing a much greater role in patients with chronic Lyme than we know. In the MyLymeData study, over 60% of patients report they were diagnosed with an additional tick-borne infection along with Lyme. For most of them, it’s Babesia.

In July 2024, researchers conducting a Lyme disease pilot study at North Carolina State University discovered that all seven participants were infected with Babesia, and six out of the seven were co-infected with at least one (sometimes two or more) species of Bartonella.

Babesia is a parasite, similar to malaria. It requires a separate test and special anti-parasitic medications outside of the standard tests and antibiotics used for Lyme disease alone.

Diagnostics

As I wrote about in December 2023, Borrelia (Lyme) has some unique features allowing it to hide from our immune system. That stealth technique, which keeps the number of bacteria low in the blood stream, also makes it difficult for standard blood tests to detect Lyme disease. In April of 2024, Dr. Michal Tal and her team published another clue as to how Borrelia hides from the immune system.

Right now, all eyes are on the six teams competing in the LymeX diagnostic challenge as they move forward with their innovations. These will hopefully result in a more accurate test becoming available to the public than the standard outdated test that has been around since 1994. (Note: Lyme X Phase 3 winners will be announced soon.)

While an accurate Lyme diagnostic is absolutely needed, I cannot ignore the fact that ticks in North America are known to transmit over 18 different pathogens.

In August of 2024, a team of biologists at City University of New York Graduate Center produced a genetic analysis of 47 different strains of Borrelia. This may pave the way for improved diagnosis, treatment, and prevention of Lyme disease.

I hope that with this new genetic mapping, we will finally be able to take advantage of the next-generation metagenomic testing which is capable of detecting multiple pathogens.

Treatment

One of the top priorities of patients with chronic Lyme disease is finding an effective treatment.

Two recent studies have shown that combination therapy for Lyme, and combination therapy for Babesia work better than monotherapy.

But not everyone responds favorably to pharmaceuticals. One reason for this, may be a condition called alpha-gal syndrome (AGS).

AGS is triggered by the bite of a tick and causes an allergy to anything derived from red meats including some medications. An estimated 450,000 people have AGS in the U.S., making it the tenth most common food allergen.

If enacted, the Alpha-Gal Inclusion Act would require the FDA to list alpha-gal as a major allergen and require labeling to include it as an ingredient.

Mast cell activation syndrome

Another complicating factor common in patients with chronic Lyme is mast cell activation syndrome (MCAS). MCAS can make patients extremely sensitive to certain types of chemicals, foods and additives.

In fact, MCAS is such an important topic, in 2024 we devoted an entire issue of the Lyme Times to Mast Cell Activation Syndrome which you can download and read for free.

Alas, there is nothing simple about treating complex medical conditions triggered by the bite of a tick. Many of the patients I know who’ve gotten better took years before they found the root cause of their misery followed by the right combination of treatment that worked.

In 2023 we devoted an entire issue of the Lyme Times trying to answer the question: What does it take to get better?

My hope is that we continue to see scientific progress in finding better diagnostics and treatment. And if you are struggling with a chronic illness, please do not give up hope.

LymeSci is written by Lonnie Marcum, a physical therapist and mother of a daughter with Lyme. She served two terms on a subcommittee of the federal Tick-Borne Disease Working Group. Follow her on X: @LonnieRhea   Email her at: lmarcum@lymedisease.org.

_______________

**Comment**

To my knowledge, treating this complex illness has hardly moved forward in over 40 years.  The medical industrial complex is myopically focused on ‘vaccines,’ which are big money makers for both Big Pharma and the government, which owns patents on many aspects of them.  As long as this remains the singular focus, patients will not be treated properly.  Further, as long as ‘consensus based‘ medicine reigns, innovative doctors who dare to use their God-given brains to help patients will continue to be persecuted, leaving patients to suffer.  As it is, the only true help for Lyme/MSIDS is to get to an independent, trained, and experienced Lyme literate doctor.

For more:

Category:

Lyme, Mast Cell Activation Syndrome (MCAS), research, Testing, Ticks, Treatment

Comments Off on Lyme Disease Research in Review: Triumphs, Trials, and the Path Forward

Optimizing Exclusion Criteria For Clinical Trials of Persistent Lyme Disease Using Real-World Data

https://www.mdpi.com/2227-9032/13/1/20

Optimizing Exclusion Criteria for Clinical Trials of Persistent Lyme Disease Using Real-World Data

by Lorraine Johnson1, Mira Shapiro2, Deanna Needell3 and Raphael B. Stricker4,*
1LymeDisease.org, Los Angeles, CA 91040, USA
2Analytic Designers LLC, Bethesda, MD 20817, USA
3Department of Mathematics, University of California, Los Angeles, CA 90025, USA
4Union Square Medical Associates, 595 Buckingham Way, Suite 350, San Francisco, CA 94132, USA
*Author to whom correspondence should be addressed.
Healthcare 2025, 13(1), 20; https://doi.org/10.3390/healthcare13010020
Submission received: 15 October 2024 / Revised: 19 December 2024 / Accepted: 21 December 2024 / Published: 25 December 2024
(This article belongs to the Topic Public Health and Healthcare in the Context of Big Data)

Abstract

Background/Objectives: Although eligibility criteria for clinical trials significantly impact study outcomes, these criteria are often established without scientific justification, leading to delayed recruitment, small sample sizes, and limited study generalizability. Persistent Lyme disease (PLD) presents unique challenges due to symptom variability, inconsistent treatment responses, and the lack of reliable biomarkers, underscoring the need for scientifically justified eligibility criteria.
Objective: This study examines the effects of commonly used enrollment criteria on sample yield in PLD clinical trials using real-world data (RWD) from the MyLymeData patient registry. The study also compares the effects of these criteria on enrollment for PLD versus acute Lyme disease (ALD) trials and evaluates the scientific rationale for each criterion.
Methods: Data from 4183 Lyme disease patients enrolled in the MyLymeData registry were analyzed to assess the prevalence and cumulative impact of various criteria on sample yield. A comparative analysis of cohorts with PLD (n = 3589) versus ALD (n = 594) was conducted to identify differences in sample attrition.
Results: In a large PLD cohort study, we found that current commonly used eligibility criteria would exclude approximately 90% of patients, significantly limiting study generalizability. Substantial differences in sample attrition between PLD and ALD cohorts highlight the need for tailored criteria. The strength of scientific justification varied widely among criteria.
Conclusions: This study demonstrates the importance of using RWD to optimize eligibility criteria in PLD clinical trials. By providing insights into the balance between sample attrition and scientific justification, researchers can enhance trial feasibility, generalizability, and robustness. Our RWD sample demonstrates that researchers could substantially increase the sample yield from 10% to 64% by loosening restrictions on coinfections and misdiagnoses of chronic fatigue syndrome, fibromyalgia syndrome, and psychiatric conditions.

Category:

Lyme, research

Comments Off on Optimizing Exclusion Criteria For Clinical Trials of Persistent Lyme Disease Using Real-World Data

UN Adopts Controversial Cybercrime Treaty & New Administration Looks to Withdraw From WHO

December 31, 2024

https://reclaimthenet.org/un-cybercrime-treaty-human-rights-concerns-ratification

UN General Assembly Adopts Controversial Cybercrime Treaty Amid Criticism Over Censorship and Surveillance Risks

Global cybercrime treaty faces scrutiny over human rights safeguards and potential misuse of cross-border powers.

Didi Rankovic

Silhouette of a person holding a phone in front of a large painted eye on a red, textured background.

As we expected, even though opponents have been warning that the United Nations Convention Against Cybercrime needed to have a narrower scope, strong human rights safeguard and be more clearly defined in order to avoid abuse – the UN General Assembly has just adopted the documents, after five years of wrangling between various stakeholders.

It is now up to UN-member states to first sign, and then ratify the treaty that will come into force three months after the 40th country does that.

The UN bureaucracy is pleased with the development, hailing the convention as a “landmark” and “historic” global treaty that will improve cross-border cooperation against cybercrime and digital threats.

But critics have been saying that speech and human rights might fall victim to the treaty since various UN members treat human rights and privacy in vastly different ways – while the treaty now in a way “standardizes” law enforcement agencies’ investigative powers across borders.

Considerable emphasis has been put by some on how “authoritarian” countries might abuse this new tool meant to tackle online crime – but in reality, this concern applies to any country that ends up ratifying the treaty.

Another point of criticism has been that UN members individually already have laws that address the same issues, rendering the convention superfluous – unless it is to extend some of those authoritarian powers to the countries that don’t formally have them, and can’t outright pass them at home for political reasons.

Since the UN General Assembly adopted the resolution without a vote – after the text was previously agreed on by negotiators – it is not immediately clear how many countries might sign it next year, and ratify what would then become a legally binding document.

In the meanwhile, a spokesperson for UN Secretary-General Antonio Guterres referred to the treaty as “a demonstration of multilateralism.”

Where opponents see potential for undemocratic law enforcement practices spilling over sovereign borders, UN representatives speak about “an unprecedented platform for cooperation” that will allow agencies to exchange evidence, create a safe cyberspace, and protect victims of crimes such as child sexual abuse, scams and money laundering.

And they claim all this will be achieved “while safeguarding human rights online.” (See link for article)

_______________

https://www.dailymail.co.uk/news/article-14224123/Trump-withdraw-puppet-Beijing-Covid

Trump looks to withdraw from WHO on first day of his administration after calling the health body a puppet of Beijing for failing to hold China accountable for COVID

By OLIVIA CHRISTIE

Donald Trump‘s presidential transition team is planning an immediate withdrawal from the World Health Organization, an expert familiar with the discussions has said.

The president-elect, 78, has repeatedly called the health body a puppet of Beijing for failing to hold China accountable for the early spread of Covid-19.

Members of Trump’s team have now told experts of their intention to withdraw from the WHO on January 20 – the first day of his second term.

‘I have it on good authority that he plans to withdraw, probably on Day One or very early in his administration,’ said Lawrence Gostin, professor of global health at Georgetown University in Washington and director of the WHO Collaborating Center on National and Global Health Law.

The Financial Times was first to report on the plans, citing two experts. The second expert, former White House COVID-19 response coordinator Ashish Jha, was not immediately available for comment.

A withdrawal from the WHO would mark a dramatic shift in US global health policy and further isolate Washington from international efforts to battle pandemics.

The departure would also deny the healthy body of its biggest donor with the US providing the WHO with about 16 per cent of its funding in 2022-23. (See link for article)

For more:

Category:

Activism, Treatment, vaccines, Viruses

Comments Off on UN Adopts Controversial Cybercrime Treaty & New Administration Looks to Withdraw From WHO